ADVAIR HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVAIR HFA (ADVAIR HFA).
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
| Metabolism | Fluticasone propionate is extensively metabolized by cytochrome P450 3A4 (CYP3A4) to an inactive metabolite. Salmeterol is primarily metabolized by CYP3A4 to alpha-hydroxysalmeterol. |
| Excretion | Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%. |
| Half-life | Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours. |
| Protein binding | Fluticasone propionate: 91%; Salmeterol: 96%; primarily to albumin. |
| Volume of Distribution | Fluticasone propionate: 4.2 L/kg (large, indicating extensive tissue distribution). Salmeterol: 7.4 L/kg. |
| Bioavailability | Inhalation: Fluticasone propionate absolute bioavailability ~15-20% (orally inhaled); swallowed portion <1%. Salmeterol: absolute bioavailability ~12% (inhaled), negligible oral bioavailability. |
| Onset of Action | Inhalation: Fluticasone propionate (ICS) effects on inflammation develop over 1-2 weeks; salmeterol (LABA) bronchodilation within 30 minutes. |
| Duration of Action | Inhalation: LABA bronchodilation persists for 12 hours; ICS effect sustained with regular dosing, requiring twice-daily administration. |
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and consider initiating at lowest available strength (fluticasone 115 mcg/salmeterol 21 mcg) 2 inhalations twice daily. No adjustment for mild impairment (Child-Pugh class A). |
| Pediatric use | Not approved for pediatric patients. Safety and efficacy in children <12 years not established. |
| Geriatric use | No specific dose adjustment, but monitor for systemic corticosteroid effects and decreased bone mineral density. Use lowest effective dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADVAIR HFA (ADVAIR HFA).
| Breastfeeding | No data on fluticasone or salmeterol in human milk. Fluticasone is excreted in milk of lactating rats. Salmeterol is likely excreted in milk based on animal data. M/P ratio unknown. Caution advised; use only if clearly needed. Consider alternative agents with more safety data (e.g., inhaled corticosteroids alone) during breastfeeding. |
| Teratogenic Risk | FDA Pregnancy Category C. Fluticasone propionate and salmeterol: In animal studies, fluticasone produced fetal toxicity (reduced fetal weight, omphalocele) at subcutaneous doses ≥0.57 mg/kg/day (approximately equivalent to MRHDID on a mg/m² basis). Salmeterol caused delayed ossification and increased fetal resorption at oral doses ≥1.1 mg/kg/day (approximately 20× MRHDID). No adequate human studies. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out; avoid unless essential. Second/third trimesters: Potential for fetal growth restriction and adrenal suppression; monitor fetal growth. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs) like salmeterol increase the risk of asthma-related death. Therefore, ADVAIR HFA should only be used in patients with asthma not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved, assess the patient and consider stepping down to a single maintenance controller therapy.
| Serious Effects |
["Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures","Hypersensitivity to any ingredient, including milk proteins (contains lactose)"]
| Precautions | ["Increased risk of asthma-related death associated with LABA use","Not indicated for acute bronchospasm relief","Risk of adrenal insufficiency in patients transferring from systemic steroids","Risk of oropharyngeal candidiasis and pneumonia","Possible systemic corticosteroid effects including hypercorticism and growth suppression in children","Monitor for worsening of asthma symptoms"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Maternal: Monitor for signs of adrenal insufficiency during taper/stress; assess asthma control with spirometry (FEV1, PEFR) and symptom scores; monitor for paradoxical bronchospasm, pneumonia, increased blood pressure, and glucose intolerance. Fetal: Ultrasound for growth assessment every 4-6 weeks if prolonged use; monitor for intrauterine growth restriction (IUGR). Consider fetal heart rate monitoring if signs of preterm labor. |
| Fertility Effects | No human data on fertility impairment. Animal studies: Fluticasone had no effect on fertility in rats at subcutaneous doses up to 50 mcg/kg/day (less than MRHDID). Salmeterol showed no impairment of fertility in rats at oral doses up to 2 mg/kg/day (approximately 10× MRHDID). Theoretical risk of reversible hypothalamic-pituitary-adrenal axis suppression with high doses. |
| No clinically significant food interactions. Grapefruit juice may increase systemic exposure to fluticasone via CYP3A4 inhibition, but effect is minimal with inhaled route. Avoid alcohol consumption as it may exacerbate bronchospasm in some patients. |
| Clinical Pearls | ADVAIR HFA (fluticasone propionate/salmeterol) is a combination inhaler for maintenance therapy of asthma and COPD. It is not indicated for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Do not exceed recommended dose due to risk of adrenal insufficiency and increased cardiovascular events. Requires dose titration to lowest effective dose. Monitor for growth suppression in children, decreased bone density, and glaucoma/cataracts with long-term use. Salmeterol may increase risk of asthma-related death; use only for patients not adequately controlled on low-dose ICS. |
| Patient Advice | Use ADVAIR HFA exactly as prescribed every day, even if you have no symptoms. · Do not use to relieve sudden breathing problems; have a rescue inhaler (e.g., albuterol) available. · Rinse your mouth with water and spit after each use to prevent oral thrush. · Shake the inhaler well before each use and prime it if not used for 4 weeks. · Avoid spraying into eyes; if contact occurs, flush with water. · Tell your doctor if you have worsening symptoms, increased rescue inhaler use, or side effects like tremor, palpitations, or oral candidiasis. |